Arcadia Biosciences, Inc.
RKDA Nasdaq· Crude Petroleum & Natural Gas
Last close · Oct 26, 2026
$0.15
KIRA · Stoqly’s AI analyst, in plain words
- Arcadia Biosciences, Inc. had $4.9M of revenue in fiscal 2025, down 3.7% on the year before. Over five years, revenue changed −9.6% a year on average.
- Its operating margin was −51.5%, up 20.8 pts: of every 100 in sales, about −51 is left after running the business.
- Arcadia Biosciences, Inc. lost $2.3M in fiscal 2025.
- Free cash flow was −$4.7M in fiscal 2025, −96.7% of revenue.
Market cap
$0.5M
P/E
—
Revenue
$4.9M
Net income
−$2.3M
Free cash flow
−$4.7M
Operating margin
−51.5%
Arcadia Biosciences, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−3.7%
No. Sales fell 3.7% last year.
Does it make a profit?
−48.1%
No. It lost money last year.
Does profit turn into cash?
−96.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Arcadia Biosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- Arcadia Biosciences, Inc.
- CIK
- 0001469443
Arcadia Biosciences, Inc. · RKDA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $6.8M | $7.4M | $4.5M | $5.0M | $4.9M |
| Revenue growth | −15.6% | 9.4% | −40.0% | 13.3% | −3.7% |
| Net interest income | −$0.0M | $0.3M | $0.7M | $0.8M | $0.2M |
| Gross margin | −28.4% | 17.8% | 51.2% | 41.3% | 36.2% |
| Operating margin | −524.0% | −188.8% | −137.0% | −72.3% | −51.5% |
| Net income | −$14.7M | −$15.4M | −$14.0M | −$7.0M | −$2.3M |
| Net margin | −216.2% | −207.3% | −313.9% | −139.5% | −48.1% |
| Diluted EPS | −$27.56 | −$25.65 | −$11.29 | −$5.17 | −$1.71 |
| Cash | |||||
| Cash from operations | −$25.9M | −$14.0M | −$15.3M | −$9.6M | −$4.7M |
| Capital expenditure | $1.0M | $0.1M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$26.9M | −$14.0M | −$15.3M | −$9.6M | −$4.7M |
| FCF margin | −396.4% | −189.4% | −343.5% | −191.1% | −96.7% |
| Share count change | −94.7% | 12.7% | 106.4% | 10.2% | 0.4% |
| Debt and strength | |||||
| Cash and short-term investments | $28.7M | $20.6M | $11.6M | $4.2M | $4.6M |
| Debt incl. finance leases | $0.0M | — | — | — | — |
| Shareholders' equity | $31.1M | $21.0M | $12.8M | $6.2M | $4.1M |
| Current ratio | 7.0x | 6.0x | 4.2x | 3.6x | 3.1x |
| Interest coverage | −1,776.3x | — | — | — | — |
| Returns and quality | |||||
| Return on capital | −1,165.5% | — | — | — | — |
| Return on equity | −49.8% | −59.0% | −82.5% | −73.8% | −45.1% |
| Return on tangible equity | −47.9% | −73.2% | −109.2% | −113.8% | −57.0% |
| Piotroski F-score | 3 | 3 | 1 | 2 | 2 |
| Altman Z'' | −15.1 | −24.8 | −41.3 | −64.9 | −136.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Arcadia Biosciences, Inc. · RKDA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.15 a share, the company is worth $0.5M.
Source: SEC EDGAR XBRL filings (CIK 0001469443). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.